Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Biphenotypic, Acute 3Hodgkin Disease 3Neutropenia 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Monocytic, Acute 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk 1Osteosarcoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, AIDS-Related 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Cyclophosphamide 34Doxorubicin 24fludarabine phosphate 20Vinblastine 20Nivolumab 20Dacarbazine 20Brentuximab Vedotin 20pembrolizumab 19fludarabine 18Mycophenolic Acid 17Whole-Body Irradiation 15Etoposide 15Filgrastim 13Melphalan 12Granulocyte Colony-Stimulating Factor 10Gemcitabine 10Bleomycin 10Tacrolimus 9Radiotherapy 9Prednisone 9Peripheral Blood Stem Cell Transplantation 9Busulfan 9Specimen Handling 8Vincristine 7Sirolimus 7Magnetic Resonance Spectroscopy 7Cyclosporine 7pegfilgrastim 6Stem Cell Transplantation 6Bendamustine Hydrochloride 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Hodgkin Disease × pegylated granulocyte colony-stimulating factor × 1 year × Clear all
NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

NCT07020533 2026-03-27

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

City of Hope Medical Center

Phase 1 Recruiting
46 enrolled
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04871607 2025-12-04

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

City of Hope Medical Center

Phase 2 Recruiting
33 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡